-
Mashup Score: 1
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease - 5 hour(s) ago
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old - 6 hour(s) ago
The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma - 11 hour(s) ago
Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer - 12 hour(s) ago
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL @DrMDavids @DanaFarberNews #leusm #oncology https://t.co/pzQgjQqJnZ